Cornel Badorff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cornel Badorff has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Kirk U. Knowlton
University of California
2 shared publicationsA M Zeiher
Division of Cardiology, Department of Internal Medicine IV, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany
1 shared publicationAlexander Muelsch
From the Molecular Cardiology Unit, Department of Medicine IV (C.B., A.M.Z., S.D.), and Institute of Cardiovascular Physiology (B.F., A.M.), Goethe-University, Frankfurt, Germany; the Department of Medicine, University of California, San Diego (C.B., K.U.K.); and the Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport (R.E.R.).
1 shared publicationAndreas M. Zeiher
From the Molecular Cardiology Unit, Department of Medicine IV (C.B., A.M.Z., S.D.), and Institute of Cardiovascular Physiology (B.F., A.M.), Goethe-University, Frankfurt, Germany; the Department of Medicine, University of California, San Diego (C.B., K.U.K.); and the Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport (R.E.R.).
1 shared publicationBirgit Fichtlscherer
From the Molecular Cardiology Unit, Department of Medicine IV (C.B., A.M.Z., S.D.), and Institute of Cardiovascular Physiology (B.F., A.M.), Goethe-University, Frankfurt, Germany; the Department of Medicine, University of California, San Diego (C.B., K.U.K.); and the Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport (R.E.R.).
1 shared publicationRobert E. Rhoads
From the Molecular Cardiology Unit, Department of Medicine IV (C.B., A.M.Z., S.D.), and Institute of Cardiovascular Physiology (B.F., A.M.), Goethe-University, Frankfurt, Germany; the Department of Medicine, University of California, San Diego (C.B., K.U.K.); and the Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport (R.E.R.).
1 shared publication
Latest Publications
- 1 May 2004
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 193 (2-3) , 121-126
Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside
Genetic defects of the dystrophin-glycoprotein complex (DGC) cause hereditary dilated cardiomyopathy. Enteroviruses can also cause cardiomyopathy and we have previously described a mechanism involved in enterovirus-induced dilated cardiomyopathy: The enteroviral protease 2A directly cleaves dystrophin in the hinge 3 region, leading to functional dystrophin impairment. During infection of mice with coxsackievirus B3, the DGC in the heart is disrupted and the sarcolemmal integrity is lost in virus-infected cardiomyocytes. Additionally, dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy in vivo, suggesting a pathogenetic role of the dystrophin cleavage in enterovirus-induced cardiomyopathy. Here, we extend these experimental findings to a patient with dilated cardiomyopathy due to a coxsackievirus B2 myocarditis. Endomyocardial biopsy specimens showed an inflammatory infiltrate and myocytolysis. Immunostaining for the enteroviral capsid antigen VP1 revealed virus-infected cardiomyocytes. Focal areas of cardiomyocytes displayed a loss of the sarcolemmal staining pattern for dystrophin and β-sarcoglycan identical to previous findings in virus-infected mouse hearts. In vitro, coxsackievirus B2 protease 2A cleaved human dystrophin. These findings demonstrate that in human coxsackievirus B myocarditis a focal disruption of the DGC can principally occur and may contribute to the pathogenesis of human enterovirus-induced dilated cardiomyopathy.
- 1 May 2004
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 193 (2-3) , 121-126
Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside
Genetic defects of the dystrophin-glycoprotein complex (DGC) cause hereditary dilated cardiomyopathy. Enteroviruses can also cause cardiomyopathy and we have previously described a mechanism involved in enterovirus-induced dilated cardiomyopathy: The enteroviral protease 2A directly cleaves dystrophin in the hinge 3 region, leading to functional dystrophin impairment. During infection of mice with coxsackievirus B3, the DGC in the heart is disrupted and the sarcolemmal integrity is lost in virus-infected cardiomyocytes. Additionally, dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy in vivo, suggesting a pathogenetic role of the dystrophin cleavage in enterovirus-induced cardiomyopathy. Here, we extend these experimental findings to a patient with dilated cardiomyopathy due to a coxsackievirus B2 myocarditis. Endomyocardial biopsy specimens showed an inflammatory infiltrate and myocytolysis. Immunostaining for the enteroviral capsid antigen VP1 revealed virus-infected cardiomyocytes. Focal areas of cardiomyocytes displayed a loss of the sarcolemmal staining pattern for dystrophin and β-sarcoglycan identical to previous findings in virus-infected mouse hearts. In vitro, coxsackievirus B2 protease 2A cleaved human dystrophin. These findings demonstrate that in human coxsackievirus B myocarditis a focal disruption of the DGC can principally occur and may contribute to the pathogenesis of human enterovirus-induced dilated cardiomyopathy.
- Open Access
Torsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditis
A patient with cardiac arrest and documented torsade de pointes ventricular tachycardia is presented in whom acute coxsackievirus B2 myocarditis was identified as the most likely underlying cardiac condition. This case shows that torsade de pointes may occur as a rare manifestation of viral myocarditis. Serial serological tests and endomyocardial biopsies may be helpful in establishing a diagnosis in such patients.
Open AccessTorsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditis
A patient with cardiac arrest and documented torsade de pointes ventricular tachycardia is presented in whom acute coxsackievirus B2 myocarditis was identified as the most likely underlying cardiac condition. This case shows that torsade de pointes may occur as a rare manifestation of viral myocarditis. Serial serological tests and endomyocardial biopsies may be helpful in establishing a diagnosis in such patients.
- 31 October 2000
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (18) , 2276-2281
Nitric Oxide Inhibits Dystrophin Proteolysis by Coxsackieviral Protease 2A Through S -Nitrosylation
Background —Infection with enteroviruses like coxsackievirus B3 (CVB3) as well as genetic dystrophin deficiency can cause dilated cardiomyopathy. We recently identified cleavage and functional impairment of dystrophin by the viral protease 2A during CVB3-infection as a molecular mechanism that may contribute to the pathogenesis of enterovirus-induced cardiomyopathy. Nitric oxide (NO) is elevated in human dilated cardiomyopathy, but the relevance of this finding is unknown. In mice, NO inhibits CVB3 myocarditis. Therefore, we investigated the effects of NO on the coxsackieviral protease 2A. Methods and Results —In vitro, NO donors like PAPA-NONOate inhibited the cleavage of human and mouse dystrophin by recombinant coxsackievirus B protease 2A in a dose-dependent manner (IC 50 , 51 μmol/L). In CVB3-infected HeLa cells, addition of the NO donor SNAP inhibited protease 2A catalytic activity on dystrophin. Because this inhibitory effect was reversed by the thiol-protecting agent DTT, we investigated whether NO S -nitrosylates the protease 2A. In vitro, NO nitrosylated the active-site cysteine (C110) of the coxsackieviral protease 2A, as demonstrated by site-directed mutagenesis. Within living COS-7 cells, SNAP-induced S -nitrosylation of this site was confirmed with electron spin resonance spectroscopy. Conclusions —These data demonstrate inactivation of a coxsackieviral protease 2A by NO through active-cysteine S -nitrosylation in vitro and intracellularly. Given that the enteroviral protease 2A cleaves mouse and human dystrophin, NO may be protective in human heart failure with an underlying enteroviral pathogenesis through inhibition of dystrophin proteolysis.
- 31 October 2000
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (18) , 2276-2281
Nitric Oxide Inhibits Dystrophin Proteolysis by Coxsackieviral Protease 2A Through S -Nitrosylation
Background —Infection with enteroviruses like coxsackievirus B3 (CVB3) as well as genetic dystrophin deficiency can cause dilated cardiomyopathy. We recently identified cleavage and functional impairment of dystrophin by the viral protease 2A during CVB3-infection as a molecular mechanism that may contribute to the pathogenesis of enterovirus-induced cardiomyopathy. Nitric oxide (NO) is elevated in human dilated cardiomyopathy, but the relevance of this finding is unknown. In mice, NO inhibits CVB3 myocarditis. Therefore, we investigated the effects of NO on the coxsackieviral protease 2A. Methods and Results —In vitro, NO donors like PAPA-NONOate inhibited the cleavage of human and mouse dystrophin by recombinant coxsackievirus B protease 2A in a dose-dependent manner (IC 50 , 51 μmol/L). In CVB3-infected HeLa cells, addition of the NO donor SNAP inhibited protease 2A catalytic activity on dystrophin. Because this inhibitory effect was reversed by the thiol-protecting agent DTT, we investigated whether NO S -nitrosylates the protease 2A. In vitro, NO nitrosylated the active-site cysteine (C110) of the coxsackieviral protease 2A, as demonstrated by site-directed mutagenesis. Within living COS-7 cells, SNAP-induced S -nitrosylation of this site was confirmed with electron spin resonance spectroscopy. Conclusions —These data demonstrate inactivation of a coxsackieviral protease 2A by NO through active-cysteine S -nitrosylation in vitro and intracellularly. Given that the enteroviral protease 2A cleaves mouse and human dystrophin, NO may be protective in human heart failure with an underlying enteroviral pathogenesis through inhibition of dystrophin proteolysis.